David Brown
Endocrinology, Diabetes & Metabolism · Rockville, MDNPI 1114044906
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Corcept Therapeutics at 56.4% of the total. Reporting peaked in 2019 at $138,807 and has fallen 79.4% since, to $28,561 in 2025. Among endocrinology, diabetes & metabolism clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 475 payments — averaging $1045.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$280K
- Novo Nordisk$204K
- Merck$8K
- Biomarin Pharmaceutical Inc.$3K
- BETA Bionics, Inc.$144
- Aerin Medical Inc.$144
- plus $421 from 6 others
What the payments were for
- Consulting fees$124,58825%
- Speaking & faculty fees$291,16159%
- Travel & lodging$70,03214%
- Food & beverage$10,7262%
- Education$2540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 290 | $280,251 |
| Novo Nordisk | 166 | $204,066 |
| Merck | 10 | $8,494 |
| Biomarin Pharmaceutical Inc. | 1 | $3,240 |
| BETA Bionics, Inc. | 1 | $144 |
| Aerin Medical Inc. | 1 | $144 |
| Dexcom, Inc. | 1 | $125 |
| Mentor Worldwide LLC | 1 | $121 |
| Lilly USA, LLC | 1 | $69 |
| Radius Health, Inc. | 1 | $51 |
| Amgen | 1 | $37 |
| Johnson & Johnson | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$276,061
- RYBELSUS$89,767
- Ozempic$82,969
- Tresiba$10,715
- STEGLATRO$5,698
- Palynziq$3,240
- Kuvan$3,240
- JANUVIA$2,625
- Xultophy 100/3.6$2,153
- iLet Bionic Pancreas$433
- iLet Insulin Infusion Kit Inset$144
- iLet Insulin Infusion Kit Contact Detach$144
- VIVAER STYLUS$144
- RHINAER STYLUS$144
- DEXCOM G7 GSS (161)$125
- MemoryGel Breast Implants$121
- FlexHD Acellular Hydrated Dermis$121
- MemoryShape Breast Implants$121
How this compares
$496,761 in reported general payments places this provider in the 95th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 59 | $2,290,799 |
| OzempicSemaglutide | 109 | $186,282 |
| MounjaroTirzepatide | 76 | $119,313 |
| TymlosAbaloparatide | 20 | $71,672 |
| TrulicityDulaglutide | 31 | $56,834 |
| JardianceEmpagliflozin | 34 | $53,536 |
| Repatha SureclickEvolocumab | 35 | $52,844 |
| FarxigaDapagliflozin Propanediol | 27 | $38,202 |
| VascepaIcosapent Ethyl | 42 | $35,345 |
| Tresiba Flextouch U-100Insulin Degludec | 47 | $31,846 |
| KerendiaFinerenone | 14 | $25,338 |
| ProliaDenosumab | 12 | $20,121 |
| JanuviaSitagliptin Phosphate | 14 | $15,940 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 21 | $14,530 |
| Ezetimibe | 215 | $10,081 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $280,251 | $2,290,79959 claims |
| Novo NordiskOzempic | $204,066 | $186,282109 claims |
| Lilly USA, LLCMounjaro, Trulicity | $69 | $176,147107 claims |
| Radius Health, Inc.Tymlos | $51 | $71,67220 claims |
| AmgenProlia | $37 | $20,12112 claims |
| MerckJanuvia | $8,494 | $15,94014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Rockville
- Helena RodbardRockville$468K
- Gerti TashkoRockville$106K
- Jie HeRockville$26K
- Monika MannanRockville$8K
- Daniel GozziSuitland$1.2M
- Martin SarkarFrederick$1.1M
- Nicholas ArgentoLaurel$1.1M
- Romeu AzevedoCamp Springs$987K
- Philip LevinBaltimore$489K
- Roy PhillipsBel Air$208K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.